Junshi Biotech announced that its wholly-owned subsidiary Topalai Biomedical Hong Kong Co., Ltd. has obtained approval from the Hong Kong Pharmacy and Poison Administration, and that treprilizumab has been approved for marketing in Hong Kong, China for the treatment of nasopharyngeal cancer.

Zhitongcaijing · 10/15 09:09
Junshi Biotech announced that its wholly-owned subsidiary Topalai Biomedical Hong Kong Co., Ltd. has obtained approval from the Hong Kong Pharmacy and Poison Administration, and that treprilizumab has been approved for marketing in Hong Kong, China for the treatment of nasopharyngeal cancer.